Asta Medica, Aktiengesellschaft

J&uuml;rgen Rawert

Thomas Reissmann

J&uuml;rgen Engel

Hilde Riethm&uuml;ller-Winzen

A regime for therapeutic management of a benign prostatic hyperplasia and prostatic cancer employs Cetrorelix alone or in combination with &agr;-reductase inhibitors or &agr;-receptor blocking agents. The regiment reduces the volume of the prostate and avoids the side effects associated with testosterone levels being in a castration range. Cetrorelix is administered at dosages between 0.5 mg/day and 20 mg/week or about 0.014 mg/kg body weight per day to 0.30 mg/kg body weight per week or at levels of about 25 to 120 mg of Cetrorelix per month or 0.376 mg/kg to 1.71 mg/kg per month. Cetrorelix can be administered with &agr;-reductase inhibitors or a &agr;-receptor blocking agents.

Growing community of inventors

Alzenau, Germany

Jürgen Rawert

Growing community of inventors

Alzenau, Germany

J&uuml;rgen Rawert

Jürgen Rawert